Keymed Biosciences, Inc. (HK:2162)
:2162
Want to see HK:2162 full AI Analyst Report?
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$39.50 - HK$81.85
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$17.70B
Enterprise ValueHK$15.95B
Total Cash (Recent Filing)HK$1.96B
Total Debt (Recent Filing)HK$788.88M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 01, 2026EPS Estimate
6.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding298,735,570
10 Day Avg. Volume1,976,819
30 Day Avg. Volume1,752,076
Financial Highlights & Ratios
PEG Ratio4.63
Price to Book (P/B)4.74
Price to Sales (P/S)18.85
P/FCF Ratio-12.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$85.48Price Target Upside36.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2
Revenue Forecast (FY)HK$2.14B
Bulls Say, Bears Say
Bulls Say
Diversified Biopharma Revenue ModelKeymed’s business model includes out-licensing, milestone and royalty income plus eventual product sales and platform/service revenue. This durable mix reduces single-product binary risk, creates multiple non-dilutive cash inflection points, and supports runway extension versus pure early-stage spenders.
Solid Balance Sheet / Low LeverageA sizable equity base (~2.78bn) and moderate leverage (~0.28x) provide financial flexibility to fund R&D and absorb trial setbacks. Asset growth supports ongoing investment, enabling partnerships or selective M&A without immediate heavy refinancing, which strengthens longer-term strategic optionality.
Revenue Scale & Strong Gross MarginsRevenue expansion from early-stage levels to ~698m and a high gross margin (~74%) indicate the company can generate meaningful top-line and efficient product-level economics. High gross margins are durable for biologics and create the potential to leverage scale into improved operating leverage if R&D and SG&A are managed.
Bears Say
Sustained Negative Cash FlowPersistent negative operating cash flow and deeply negative free cash flow (-1.05bn in 2025) signal ongoing cash burn that will pressure runway. Over the medium term this necessitates external financing, asset monetization, or partnership revenue; all increase dilution or constrain strategic flexibility until cash generation stabilizes.
Large Operating And Net LossesVery large operating and net losses reflect heavy R&D and SG&A relative to revenues. Even with strong gross margins, continued negative EBIT and net margins mean profitability hinges on successful clinical outcomes or licensing deals—both multi-year and uncertain—keeping earnings recovery distant without structural change.
Volatile Revenue TrendAfter rapid historical scaling, a ~20% YoY revenue decline in 2025 shows revenue volatility and timing sensitivity to partnerships or milestone recognition. This variability complicates forecasting, weakens predictability of cash flows, and delays the firm’s ability to rely on stable commercial revenue to offset R&D-driven losses.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$39.50 and its highest was HK$81.85 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$17.70B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Mar 26, 2026. The company reported -HK$1.839 earnings per share for the quarter, missing the consensus estimate of -HK$1.501 by -HK$0.338.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is 6.58.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$1.839 in its last earnings report, missing expectations of -HK$1.501. Following the earnings report the stock price went up 0.174%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$85.48 (36.11% Upside)
HK$85.48 (36.11% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.01%
12-Months-Change
Fundamentals
Return on Equity
-17.26%
Trailing 12-Months
Asset Growth
17.19%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
2162 Stock 12 Month Forecast
Average Price Target
HK$85.48
▲(36.11% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Simcere Pharmaceutical Group Limited
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---